Furthermore, the enhanced expression of NDRG2 suppressed the vulnerability and degradation of client proteins upon treatment with CMP5 and HLCL61 in NDRG2low ATL and solid cancer cell lines, indicating that the targeting of PRMT5/MEP50 enzymatic activity is a feasible and effective strategy for promoting cancer vulnerability in NDRG2low ATL and various cancer cells. This evidence concerns the gene PRMT5 and cancer.